MYDA Advisors LLC Has $3.03 Million Stock Position in Benitec Biopharma Limited $BNTC

MYDA Advisors LLC grew its stake in shares of Benitec Biopharma Limited (NASDAQ:BNTC) by 221.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 225,000 shares of the biotechnology company’s stock after buying an additional 155,000 shares during the quarter. MYDA Advisors LLC’s holdings in Benitec Biopharma were worth $3,031,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Barclays PLC raised its holdings in shares of Benitec Biopharma by 9.1% during the fourth quarter. Barclays PLC now owns 23,211 shares of the biotechnology company’s stock valued at $313,000 after purchasing an additional 1,928 shares during the period. Nantahala Capital Management LLC raised its holdings in shares of Benitec Biopharma by 23.9% during the fourth quarter. Nantahala Capital Management LLC now owns 1,038,371 shares of the biotechnology company’s stock valued at $13,987,000 after purchasing an additional 200,276 shares during the period. Marshall Wace LLP bought a new stake in shares of Benitec Biopharma during the fourth quarter worth about $481,000. AWM Investment Company Inc. increased its position in shares of Benitec Biopharma by 54.7% during the fourth quarter. AWM Investment Company Inc. now owns 282,977 shares of the biotechnology company’s stock worth $3,812,000 after acquiring an additional 100,000 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Benitec Biopharma during the fourth quarter worth about $10,102,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Price Performance

NASDAQ:BNTC opened at $11.18 on Monday. The firm has a 50-day moving average of $11.72 and a 200-day moving average of $11.84. The company has a market cap of $384.03 million, a PE ratio of -9.81 and a beta of 0.27. Benitec Biopharma Limited has a one year low of $9.85 and a one year high of $17.10.

Benitec Biopharma (NASDAQ:BNTC) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.03. On average, equities research analysts expect that Benitec Biopharma Limited will post -1.04 earnings per share for the current fiscal year.

Analyst Ratings Changes

BNTC has been the subject of several recent research reports. TD Cowen reissued a “buy” rating on shares of Benitec Biopharma in a research report on Monday, March 9th. Guggenheim downgraded shares of Benitec Biopharma from a “buy” rating to a “neutral” rating in a research report on Wednesday. Wall Street Zen downgraded shares of Benitec Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a research report on Monday, April 20th. Finally, Evercore initiated coverage on shares of Benitec Biopharma in a research report on Tuesday, May 12th. They set an “outperform” rating and a $25.00 target price for the company. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $27.00.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.